Memphis Pharmaceuticals results, Q3 2025
Net profit, assets, equity and cash flow for Q3 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit108 millionEGP · +29.0% vs the same period a year earlier
Total assets1.48 billionEGP · +31.6% vs the same period a year earlier
Shareholders' equity661 millionEGP · +875.4% vs the same period a year earlier
Operating cash flow65.2 millionEGP · +170.4% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q3 2025 was about 108 million EGP, up +29.0% from 83.48 million EGP in Q3 2024.
- Total assets at the end of Q3 2025 were about 1.48 billion EGP, and shareholders' equity about 661 million EGP.
- Operating cash flow for Q3 2025 was positive at 65.2 million EGP.
Key lines against the same period a year earlier
This periodQ3 2024Change
Net profit108 million83.48 million+29.0%
Gross profit130 million78.75 million+65.4%
Total assets1.48 billion1.13 billion+31.6%
Total liabilities—1.06 billion—
Shareholders' equity661 million67.73 million+875.4%
Total liabilities and equity1.48 billion1.13 billion+31.6%
Operating cash flow65.2 million-92.61 million+170.4%
Investing cash flow31.76 million5.58 million+469.4%
Financing cash flow56.18 million64.91 million−13.4%
Net change in cash—-22.12 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy